middle.news
How Vectus Biosystems’ $4.5M XORTX Deal Could Unlock Global Licensing Growth
7:01am on Friday 31st of October, 2025 AEDT
•
Healthcare
Read Story
How Vectus Biosystems’ $4.5M XORTX Deal Could Unlock Global Licensing Growth
7:01am on Friday 31st of October, 2025 AEDT
Key Points
Binding agreement with XORTX for VB4-P5 renal fibrosis compound
Deal valued at approximately A$4.5 million in shares and warrants
Ongoing licensing discussions for lead compound VB0004 and other candidates
Focus on commercialisation and potential partnerships in China
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Vectus Biosystems (ASX:VBS)
OPEN ARTICLE